Abstract
Introduction

39
We and others have demonstrated that red cells are an important source of the plasma phospholipid 40 sphingosine-1-phosphate (S1P) which acts continuously to maintain normal vascular permeability (7, 9, 41 24, 34, 43, 50) . The aim of the present experiments was to investigate mechanisms that control the 42 delivery of S1P from red blood cells (RBCs) to the endothelium in intact microvessels. Our specific focus 43 was the action of albumin as a carrier of S1P and as a modulator of vascular permeability. It has been 44 known for many decades that the presence of albumin in vascular perfusates stabilizes the endothelial 45 barrier (13, 14, 18, 23, 25, 28, 46) . Removal of plasma proteins from perfusates increases vascular 46 permeability, and results in loss of the endothelial glycocalyx (11, 29, 32, 33) . The common interpretation 47 of the action of albumin is that it forms part of the permeability barrier by electrostatic binding to the 48 endothelial glycocalyx and possibly occupying space within all or part of the intercellular junction (5, 8, 49 18, 30, 41, 47, 49) . However in the light of the new understanding of albumin as a carrier of S1P, (4, 6, 16, 50 27) we have tested the hypothesis that at least part of the action of albumin to stabilize vascular 51 permeability is its ability to bind S1P released from RBCs and thereby enhance its delivery to endothelial 52 cells where it attenuates increased permeability. Furthermore in collaboration with Tarbell's group we 53 have demonstrated that the presence of albumin contributes to the maintenance of the glycocalyx via a 54 S1P dependent mechanism (9, 49) . Thus the present experiments are designed to evaluate how the 55 presence and absence of albumin in vascular perfusates modulates the availability of S1P and the action 56 of S1P to account for the well-known "protein effect" on vascular permeability. In order to enable direct 57 comparison with previous observations of the action of albumin to maintain a stable permeability in 58 individually perfused microvessels (measured as the hydraulic conductivity of the microvessel wall), we 59 began these experiments using concentrations of RBCs (hematocrits) in perfusates with and without 60 albumin that were characteristic of those used in those previous experiments. 61 62
Methods
63
Animal preparation. Animal protocol (no. 16158) was approved by the Institutional Animal Care and Use 64
Committee of the University of California, Davis. Male rats (Sprague-Dawley, 350-450 g, aged 70-90 days, 65
Hilltop Laboratory Animals, Inc.) were anesthetized with pentobarbital (100 mg/kg body weight, s.c.) and 66 subsequently maintained with additional pentobarbital (30 mg/kg, s.c.) as determined using toe pinch 67 reflex. At the end of experiments rats were euthanized with saturated KCl. During experiments rats were 68 positioned on a tray with a heating pad to maintain normal temperature. Using a midline abdominal 69 incision (2-3 cm) the mesentery was gently arranged over a cover glass or quartz pillar for microscopic 70 observation. The mesentery was continuously suffused with Ringer's solution (35˚C to 37˚C). Diameter of 71 venular microvessels chosen for study ranged from 22 to 36 µm.
73
Solutions and reagents. Mammalian Ringer's solution included (in mM) 132 NaCl, 4.6 KCl, 2 CaCl 2 , 1.2 74 MgSO 4 , 5.5 glucose, 5.0 NaHCO 3 , and 20 N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) 75
and Na-HEPES. The ratio of acid-HEPES to Na-HEPES was adjusted to achieve pH 7.40-7.45. All 76 mammalian Ringer's solution perfusates additionally contained fatty acid free BSA (Sigma A0281) at 10 77 mg/ml and test reagents or vehicle. A stock solution of S1P (1 mM) was prepared in EtOH. Stock solution 78 of S1P1 receptor antagonist W-146 (Avanti Polar Lipids, Inc.) was prepared (5 mM) with 2% 2-79 hydroxypropyl-β-cyclodextrin in Ringer; W-146 was diluted to working concentration (10 µM and 80 0.004% 2-hydroxypropyl-β-cyclodextrin).
82
To measure permeability to tracer albumin, fatty acid free BSA (Sigma A0281; 66 kDa, 3.6 nm Stokes 83 radius) was labeled with Alexa Fluor 555 (emission max 570 nm) according to manufacturer (Invitrogen) 84 instructions to produce BSA-555 with a labeling efficiency of 3-5 moles of dye per mole of protein and 85 then processed to reduce free dye concentration as previously described (9, 26 
Results
49
Exogenous S1P maintains normal permeability when the absence of albumin increases solute 50 permeability 51
In agreement with our previous observations (9) perfusate containing albumin (10 mg/ml) when 52 conditioned by exposure to RBCs (hematocrit 1.3%) for a period of 20 min maintains the normal P s of 53 individually perfused microvessels (0.92 ± 0.38 × 10 -6 cm/s, n = 9; Fig 1) . That previous study also 54
showed that perfusate containing albumin (10 mg/ml), but not conditioned by RBCs, fails to maintain Ps 55 (15.3 ± 6.3× 10 -6 cm/s). In contrast, a Ringer perfusate without BSA, but conditioned with RBCs, does not 56 maintain normal permeability (16.1 ± 3.9 × 10 -6 cm/s; p<0.05). In 6 of the experiments (as illustrated in 57 Fig 1A) we found that the addition of exogenous S1P (1000 nM) rapidly restored normal permeability in 58 microvessels perfused with Ringer or RBC-conditioned Ringer in absence of BSA (0.83 ± 0.18 × 10 -6 59 cm/s).
61
The striking difference between the stability of solute permeability when albumin is present, and the 62 increased permeability when albumin was not present, is consistent with a role for albumin to modulate 63 the availability of S1P. However the observation that exogenous S1P reverses the increased solute 64 permeability of the Ringer perfused vessels suggests that, when sufficient S1P is available, albumin is not 65 essential to maintain the low permeability state. These observations are consistent with the hypothesis 66 that S1P is the primary modulator of the well described "protein effect" to lower permeability. 67 68
Direct measurements of S1P in perfusates with and without albumin 69
The average concentration of S1P in the Ringer/BSA perfusate conditioned with RBCs (1.3% Hct) for 20 70 minutes at room temperature as used in the experiments in Figure 1 was 439 ± 46 nM (n=12; Fig 2) . In 71 the absence of albumin the mean concentration of S1P measured in Ringer perfusate after 20 minutes 72 exposure to red cells was more than an order of magnitude lower (28 ± 5 nM; n=13). 73 74
The differences in S1P concentrations in conditioned media with and without albumin were even more 75 striking at 37°C. Ringer perfusates conditioned with RBC (1.3% Hct) at 37°C had an average S1P 76 concentration of 52 ± 8 nM (n=20), while in the presence of BSA the RBC-conditioned solution had 1350 77 nM S1P. These values in protein-free Ringer solutions are close to an order of magnitude less than the 78 corresponding S1P concentrations in solutions with BSA (10 mg/ml). All values are in Figure 2 . The 79 figure also demonstrates that S1P release from red cells at 37°C is strongly dependent on albumin 80 concentrations, falling to 220 ± 19 nM for S1P conditioned in the presence of 1 mg/ml albumin and 50 ± 81 10 nM at 0.1 mg/ml albumin (Hct 1.3%, 37°C). We measured S1P in our BSA (10 mg/ml) solution without 82 preconditioning and found that it contained S1P at 75 ± 2 nM. When combined with the results in Figure  83 1, these measurements show that concentrations of S1P in conditioned media below 100 nM fail to 84 maintain normal permeability whereas concentrations of 440 nM and above maintain permeability. This 85 conclusion is based on the assumption that results from in vitro preconditioning are representative of 86 S1P levels in the perfusates in a micropipette immersed in the superfusate at 37°C before perfusion of the 87 test microvessel. 88 89
Further evaluation of exogenous S1P regulation of solute permeability 90
A direct test of the dependence of solute permeability on S1P concentration is shown in Figure 3A . These 91 results extend the observation in Figure 1 to shown that Ps measured with Ringer perfusates with 92 exogenous S1P added at concentrations of 1000 nM (as in Fig 1) at a temperature of 37°C) there was no increase in L p relative to control (albumin present). To test if the 08 stable L p was due to S1P released into the perfusate, we added an S1P1 antagonist to the Ringer/RBC 09 perfusate. Figure 4 shows that the stable permeability state with Ringer and continuously present RBCs 10 was reversed using the S1P1 antagonist W146. Thus at 37°C, a Ringer perfusate in constant contact with 11
RBCs in a pipette contains sufficient S1P to maintain permeability, whereas at lower temperatures there 12 appears to be insufficient S1P available for the stable state to be maintained. The results also indicate that 13 at 37°C the S1P concentrations measured after conditioning Ringer with RBCs in vitro before filling the 14 pipette may underestimate S1P concentration in a Ringer solution that remains in contract with RBCs in 15 the pipette. 16 17
Absence of RBCs and albumin increases hydraulic conductivity 18
To further evaluate the role of RBCs as an exogenous source of S1P when the perfusate was protein-free 19
Ringer we replaced RBCs with relatively large liposomes, which acted as flow markers, but produced no 20 S1P. Consistent with earlier results (Fig 1) , Figure 5 shows that L p first measured in the presence of BSA 21
and RBCs with control value of 0.8 ± 0.1 × 10 -7 cm/(s × cmH 2 O) increased significantly to the test value of 22 2.6 ± 0.3 × 10 -7 cm/(s × cmH 2 O) measured during protein-free Ringer perfusion using liposomes as flow 23 markers (n=9, p<0.05). As a further test, in 5 experiments we compared L p during RBC-conditioned BSA 24 perfusion (no RBCs during perfusion) versus Ringer only, both using liposomes as flow markers, and 25
found that RBC-conditioning significantly decreased L p from 2.7 ± 0.5 × 10 -7 cm/(s × cmH 2 O) to 1. 
Discussion
32
Our results conform to the hypothesis that the primary action of albumin to maintain vascular 33 permeability is to facilitate the release of S1P from erythrocytes, rather than to act directly by binding to 34 the endothelial surface to form part of the barrier to water and solute as previously suggested. Albumin is 35 not required to maintain normal permeability when S1P is present at sufficient amounts in the perfusate.
36
The lowest S1P concentration that maintains a stable permeability is above 100 nM. For perfusates that 37 have been conditioned by exposure to RBCs for 20 minutes with 10 mg/ml albumin, S1P concentrations 38 between 300 and 500 nM (mean 440 nM) are sufficient to maintain normal permeability. These results 39 extend our previous observation that removing S1P or inhibiting its action by use of an S1P1 receptor 40 antagonist (W146) leads to an increase in microvascular permeability (9). In those experiments we also 41 demonstrated that an S1P1 receptor agonist (sew2871) was effective to return P s to normal when 42 permeability had increased after RBCs were removed from the perfusate (9). To place these new results 43 in the context of the current understanding of mechanisms maintaining normal microvascular 44 permeability, this discussion is divided into three main sections: First, cellular mechanisms whereby S1P 45 maintains normal permeability are described and these are evaluated as an alternative to the model of 46 physical interaction between albumin and the endothelial cell glycocalyx to increase resistance to water 47 and solute flow. Second, the results are evaluated in relation to the growing understanding of the role of 48 albumin and the other S1P carriers (e.g. high density lipoproteins, HDL) to facilitate the release of S1P 49 into plasma. Third, the importance of these results to the interpretation of experiments conducted in vivo 50 and in vitro under different perfusion conditions is discussed. These include the use of solutions with and 51 without plasma proteins including fetal calf serum (FCS) and albumin, at various concentrations in 52 bathing media, and in the presence and absence of RBCs as a source of S1P. 53 54
Cellular Mechanisms 55
The mechanisms of action of S1P have been reviewed in recent publications (12, 45). Ligation of the G 56 protein-coupled S1P1 receptor rapidly activates the Rho family small GTPase Rac1, leading to peripheral 57 localization of cytoskeletal effectors (e.g., cortactin, non-muscle myosin light chain kinase). This 58 localization promotes adherens junction (including VE-cadherin, associated catenins) and tight junction 59 (occludin, ZO proteins, claudins) formation. Cell-substrate (via paxillin and focal adhesion kinase) as well 60 as cell-cell adhesion is increased. These changes all serve to improve barrier function. A second 61 mechanism of action is to stabilize the endothelial glycocalyx. We have recently demonstrated that 62 heparin sulfate (HS), chondroitin sulfate (CS), and syndecan-1 ectodomain, which are shed from cultured 63 endothelial cells after removal of plasma proteins, were retained in the presence of S1P. S1P was found to 64 reduce matrix metalloproteinase (MMP) activation thereby attenuating the loss of endothelial cell surface 65 glycocalyx components (49). Both actions appear to involve signaling via receptor S1P1. The actions to 66 modulate the glycocalyx by intracellular signaling via the activity of MMPs is contrasted with the idea that 67 albumin directly modifies the resistance of water and solute flows by electrostatic interactions between 68 the positively charged arginine groups on the protein and negatively charged heparin sulfate side chains 69 of core glycoproteins such as syndecan-1 and glypican-1 (33).
71
The primary action of S1P via the S1P1 receptor accounts for some of the observations in frog 72 microvessels after albumin is removed from the perfusate that were not accounted for by a simple model 73 of albumin occupying space within a primary water channel. One is that the increased permeability with 74
Ringer perfusion was associated with an increase in intracellular calcium ion concentration in endothelial 75 cells. Further calcium free Ringer attenuated the increase in permeability. We and others have shown 76 that S1P acting via Rac1 attenuates calcium dependent increases in microvessels permeability (2, 34) . It 77 is likely that S1P also attenuates the calcium dependent mechanism that increases permeability after 78 albumin is removed from the perfusate. Another observation was that albumin added to the superfusate 79 attenuated the increase in permeability caused by removal of albumin from the perfusate. Although it 80 was suggested that such extracellular albumin might diffuse into the intercellular junction to occupy 81 space, the more likely mechanism is that S1P carried by the extracellular albumin, was sufficient to 82 stimulate S1P receptors on the endothelial cells. Another key observation consistent with the idea that 83 albumin modulates the availability of S1P which acts tonically to maintain permeability is that the 84 removal of albumin from microvessel perfusate results in a sustained increase in permeability as in 85 Figures 1 and 4 , as opposed to a transient increase in permeability which is seen with most inflammatory 86 agents (12). Further, S1P acts rapidly to modulate microvessel permeability. As shown in Figures 1 and 4 , 87 as well as in previous publications from this laboratory and others (34) , reduced levels of S1P, or 88 inhibition of the S1P1 receptor, results in a rapid increase in permeability. The increase is also rapidly 89 reversed when S1P is added back to the perfusate (2). 90 91
We note that our observations do not rule out other actions of a large macromolecule binding to the 92 endothelial surface to modulate permeability or endothelial cell uptake of circulating macromolecules.
93
The observations by Michel and colleagues (32) that cationized ferritin bound to the surface of 94 endothelial cells and reduced permeability was used as an example of how bound macromolecules could 95 modify the endothelial surface. It was assumed that positively charged arginine groups in albumin could 96 facilitate albumin binding to the endothelium (33). Such albumin binding to the endothelial surface has 97 been demonstrated (39, 40, 48) . Furthermore, the removal of albumin from the perfusate was shown to 98 increase the loading of macromolecules into vesicles on the luminal surface of endothelium (33, 38).
99
Giantsos and colleagues have described the development of cationized polymers that bind to the 00 endothelial surface and reduce the permeability of endothelial monolayers (15). Thus the role of both 01 S1P and absorbed macromolecules as modulators of transvascular transport and endothelial cell uptake 02 (including vascular targeted gene therapy agents) requires further investigations (37). 03 04 S1P delivery to plasma 05
Although platelets are an important source of S1P during injury and inflammation, S1P found in plasma 06 under normal conditions is derived largely from erythrocytes and from endothelial cells (27, 44) . The 07 mechanism of transport from the intracellular space to the plasma space is not well understood, but is 08 known to involve ATP-binding cassette (ABC-) type transporters in some cell types (22). The primary 09 acceptors and carriers of S1P in plasma are albumin (about 30%), HDL (about 60%), and VLDL (less than 10 10%). In the absence of these acceptors very little S1P accumulates in bathing media (6). Our 11 observations that S1P delivery is reduced as temperature, albumin concentration and hematocrit are 12 reduced are consistent with these mechanisms. The primary role of albumin as a modulator and carrier 13 of S1P possibly accounts for the observation that modified albumins are less effective to maintain 14 permeability. Thus when arginine groups are shielded on albumin, the present observations suggest that 15 the resultant reduction in the effectiveness of albumin to maintain permeability (33) is at least as likely to 16 be the result of reduced capacity to facilitate S1P release and transport as reduced electrostatic binding 17 to the endothelium. While complete removal of albumin from a perfusate is not physiological, the above 18 observations indicate that conditions that reduce the capacity of albumin to bind S1P may compromise 19 permeability regulation. Such conditions possibly include glycation of albumin (36) and the 20 apolipoprotein M in HDL, as well as competition for the S1P binding sites by other drugs or toxins.
22
A key observation is that even with the lowest conditioning Hct (<2%) albumin promotes S1P 23 concentrations of 1350 nM in vitro when compared to 52 nM in the absence of albumin. This implies that 24 albumin increases the release of S1P by up to 25 times. Even higher rates of release are expected at 25 higher Hct. Yet normal S1P concentrations in blood plasma are 300-400 nM (35). This observation 26
suggests that, in the normal circulation, S1P is rapidly removed from plasma and an important 27 physiological role for albumin is to promote the delivery of S1P from RBCs to maintain S1P levels. While 28 further investigations of the modulation of the kinetics of S1P supply and removal are needed in the 29 whole circulation it is reasonable to argue that the actions of albumin as a promoter of S1P release and as 30 a carrier (along with HDL) contribute to the balance between the rate of supply of S1P from red cells and 31 the rate of removal. Our observations that S1P can be supplied to individually perfused microvessels 32 without albumin suggest that the mechanisms removing S1P from the whole circulation are not present 33 in microvessels under the conditions of our microperfusion experiments.
35
Re-evaluation of the protein effect as a determinant of normal vascular permeability 36
In a separate collaborative study between our laboratory and the Tarbell laboratory we have 37 demonstrated that S1P maintains the stability of the endothelial glycocalyx in cultured endothelial cell 38 monolayers (49). The role of albumin and plasma proteins as modulators of S1P delivery from RBCs 39 likely accounts for observations of changes in the glycocalyx in protein free perfusates. Specifically, when 40 microvessels that had previously been labeled with cationized ferritin (CF) to reveal the surface layer of 41 the endothelial luminal glycocalyx were reperfused with plasma the CF labeled layer was found to be 42 separated from the endothelial surface by about 30 nm (1). By contrast, when vessels were reperfused 43 with protein free ringer solution the CF labeled layer remained very close (3 nm separation) to the 44 endothelial surface. Treatment with solutions containing BSA (10-50 mg/ml) resulted in separation of 45 only about 8 nm. It is tempting to speculate that the differential effect of the plasma reperfusion was due 46 to S1P in the plasma. However, the S1P concentrations in those experiments are unknown as are the 47 details of amphibian pharmacology regarding S1P. 48 49
We examined possible sources of S1P in the experimental solutions and found that commercial FCS and 50 various BSA preparations contribute significantly to S1P in solution (49). We found the fatty acid free 51 BSA used in the present study contributes 75 nM (at 10 mg/ml in Ringer) to the perfusates. We note that 52 while some studies indicate that endothelium can provide S1P to incubation media (44), removal of 53 sources of S1P from perfusion solutions in the current study uniformly resulted in increased 54 permeability, indicating that any S1P released directly from endothelium of the microvessels was 55 insufficient to maintain local normal P s . Many experiments on cultured endothelial cells or on isolated 56 vascular segments involve the use of artificial bathing fluids. Our observations indicate that the amount of 57 S1P that is available to the endothelium under these conditions depends of several factors including 58 temperature, albumin concentration, FCS concentration and RBC hematocrit. Even when albumin and 59 FCS are present our experiments demonstrate that there may be insufficient S1P available to maintain 60 the normal vascular barrier when RBCs or RBC conditioned solutions are not present. Clearly the factors 61 modulating S1P availability and the amount of S1P present in bathing solutions during experiments on 62 model endothelial barriers must be examined to investigate the stability of the barrier. Such information 63
is not available for the majority of such investigations to date. 64 65 Figure 2 . S1P measured in RBC-conditioned solutions. BSA (mg/ml), Hct (%RBC by volume), T (°C), n 07 number of independent measurements. 08 09 Figure 3 . S1P added to Ringer perfusates maintains low permeability. 
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